New enteric coating for solid dosage forms offers hope for patients with ulcerative colitis
![](/46/pdcnewsitem/04/38/44/tillots%20pharma.png)
The OPTICORE coating technology allows targeted drug release in the large intestine to improve local and/or systemic drug bioavailability.
Tillotts Pharma (Switzerland) has introduced a new advanced enteric coating for solid dosage forms at this year's annual meeting of the American Association of Pharmaceutical Scientists. The OPTICORE coating technology comprises two trigger systems and an accelerator to allow targeted drug release in the large intestine to improve local and/or systemic drug bioavailability. The inner coating layer is designed to accelerate the dissolution of the outer coating, thereby accelerating the release of the active ingredient as soon as the tablet reaches the large intestine. The pH-sensitive and enzyme-sensitive triggers together with the accelerator of the inner layer are designed to open the tablet precisely at the ileo-colonic junction to make the active ingredient available. The OPTICORE technology is particularly suitable for larger single unit formulations and offers great potential to address colon targeted delivery especially in challenging conditions of ulcerative colitis.
With the OPTICORE technology Tillotts Pharma introduces an advanced coating system for accurate site-specific colonic targeting. The combination of two physiological triggers for drug release, supported by a coating dissolution acceleration mechanism is designed to overcome the inter- and intra-individual variability in gastrointestinal physiology. It consists of an outer polysaccharide and polymer coating whose degradation is triggered by either pH or intestinal bacterial enzymes and an inner layer designated to allow for the overall bioavailability of the dissolved active ingredient throughout the target region. The coating has been successfully applied on tablets, gelatine and Hydroxy-propyl-methyl-cellulose (HPMC) capsules and the neutron-activation process does not affect the quality of the drug products.
The OPTICORE technology is designed for accurate drug delivery to the colon making it especially suitable for larger single unit formulations and offers great potential to address a colon targeted delivery especially in the challenging conditions of ulcerative colitis.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance